Enzo Biochem Current Ratio 2010-2022 | ENZ

Enzo Biochem current ratio from 2010 to 2022. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Enzo Biochem Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2022-04-30 $0.06B $0.03B 2.52
2022-01-31 $0.07B $0.03B 2.55
2021-10-31 $0.07B $0.02B 2.85
2021-07-31 $0.07B $0.03B 2.71
2021-04-30 $0.07B $0.03B 2.44
2021-01-31 $0.07B $0.03B 2.33
2020-10-31 $0.07B $0.03B 2.09
2020-07-31 $0.07B $0.03B 2.10
2020-04-30 $0.07B $0.03B 2.27
2020-01-31 $0.07B $0.02B 3.07
2019-10-31 $0.08B $0.02B 3.36
2019-07-31 $0.08B $0.02B 5.09
2019-04-30 $0.09B $0.02B 5.61
2019-01-31 $0.06B $0.02B 3.84
2018-10-31 $0.08B $0.02B 4.15
2018-07-31 $0.08B $0.02B 4.12
2018-04-30 $0.09B $0.02B 4.63
2018-01-31 $0.09B $0.02B 4.51
2017-10-31 $0.09B $0.02B 4.66
2017-07-31 $0.09B $0.02B 5.00
2017-04-30 $0.09B $0.02B 5.16
2017-01-31 $0.09B $0.02B 4.95
2016-10-31 $0.09B $0.02B 4.35
2016-07-31 $0.09B $0.02B 4.44
2016-04-30 $0.06B $0.02B 2.55
2016-01-31 $0.06B $0.03B 2.41
2015-10-31 $0.05B $0.03B 2.05
2015-07-31 $0.05B $0.02B 1.94
2015-04-30 $0.04B $0.02B 1.60
2015-01-31 $0.04B $0.02B 1.63
2014-10-31 $0.04B $0.03B 1.62
2014-07-31 $0.04B $0.03B 1.63
2014-04-30 $0.04B $0.02B 1.73
2014-01-31 $0.03B $0.02B 1.35
2013-10-31 $0.03B $0.02B 1.34
2013-07-31 $0.03B $0.02B 1.37
2013-04-30 $0.03B $0.02B 1.46
2013-01-31 $0.03B $0.02B 1.67
2012-10-31 $0.04B $0.02B 1.93
2012-07-31 $0.04B $0.02B 2.13
2012-04-30 $0.04B $0.02B 2.50
2012-01-31 $0.04B $0.02B 2.56
2011-10-31 $0.05B $0.02B 2.71
2011-07-31 $0.05B $0.02B 2.90
2011-04-30 $0.05B $0.02B 3.35
2011-01-31 $0.05B $0.02B 3.22
2010-10-31 $0.06B $0.02B 3.66
2010-07-31 $0.06B $0.02B 3.71
2010-04-30 $0.06B $0.01B 4.78
2010-01-31 $0.07B $0.02B 3.54
2009-10-31 $0.07B $0.01B 5.47
2009-07-31 $0.07B $0.01B 5.34
2009-04-30 $0.08B $0.02B 5.05
2009-01-31 $0.09B $0.01B 6.54
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.105B $0.118B
Enzo Biochem, Inc. develops, manufactures and markets health care products based on molecular biology and genetic engineering techniques, and also provides diagnostic services to the medical community. The business activities of the company are performed by one of the company's three wholly-owned subsidiaries--Enzo Diagnostics, Inc., Enzo Therapeutics, Inc., and Enzo Clinical Labs, Inc. The primary focus of the company's research is the development of products based on two technology platforms -- genetic modulation and immune modulation.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $150.984B 9.16
GSK (GSK) United Kingdom $59.709B 7.17
Bio-Rad Laboratories (BIO.B) United States $12.433B 27.47
Biohaven Pharmaceutical Holding (BHVN) United States $10.873B 0.00
QIAGEN (QGEN) Netherlands $9.383B 15.71
Ginkgo Bioworks Holdings (DNA) United States $4.998B 0.00
Arcus Biosciences (RCUS) United States $1.819B 35.51
Myovant Sciences (MYOV) United Kingdom $1.614B 0.00
Emergent Biosolutions (EBS) United States $1.040B 6.03
ADC Therapeutics SA (ADCT) Switzerland $0.376B 0.00
Zymeworks (ZYME) Canada $0.305B 0.00
Gelesis Holdings (GLS) United States $0.081B 0.00
SQZ Biotechnologies (SQZ) United States $0.068B 0.00
Ambrx Biopharma (AMAM) United States $0.041B 0.00